

Therapeutic Photobiomodulation: A Necessary Component of a Veterinary Pain Management Strategy

Ronald J. Riegel, DVM
August, 2012

The primary role of the veterinarian is to control pain and suffering and the range of tools and methods to accomplish this is ever-increasing. Therapeutic photobiomodulation, such as provided by therapy lasers, has become an important element in a multimodal approach to pain management.

The analgesic effects achieved with the administration of therapeutic photobiomodulation are well documented in the literature. The first of the peer-reviewed papers appeared in 1991 with the bulk of the documentation detailing the mechanisms and the effectiveness of this modality being presented from 2009 to 2012.^{1 2 3 4 5}

Practicing scientific, evidence-based medicine does not allow us to merely believe: “photons enter, a miracle happens, and then the pain is gone!” The mechanisms resulting in this physiological achievement are clearly understood. Photons, within the infrared spectrum, act on the endogenous photoreceptors, or chromophores, of the individual cells resulting in a biochemical cascade of events. A combination of localized and systemic enzymatic, chemical, and physical events effectively produce a state of analgesia.^{6,7,8,9}

Increased β Endorphin Release:

Once the target cells receive a therapeutic dosage of photonic energy, there is a release of β endorphins.¹⁰ “Endorphin” comes from the words endogenous + morphine. These endogenous peptides attach to the same cell receptors in the brain, spinal cord and other nerve endings that would accept morphine and act presynaptically to inhibit the release of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid).¹¹ The almost instantaneous clinical result is a reduction in pain perception coupled with a mild euphoria.

Increase in Nitric Oxide Levels:

Nitric oxide, produced in the mitochondria, can inhibit respiration, by binding to cytochrome c oxidase, thus competitively displacing oxygen. This is especially true in stressed or hypoxic cells.¹¹ Following therapeutic photobiomodulation there is a photodissociation of nitric oxide from cytochrome c oxidase thereby reversing the mitochondrial inhibition of the respiratory rate due to excessive nitric oxide binding.¹²

This increased level of nitric oxide has multiple pain relieving effects for the patient.

1. Nitric oxide serves as a neurotransmitter between nerve cells; part of its general role in redox signaling. Unlike most other neurotransmitters that only transmit information from a presynaptic to a postsynaptic neuron, the small, uncharged,

and fat-soluble nitric oxide molecule can diffuse widely and readily enters cells. Consequently, it can act on several nearby neurons, even on those not connected by a synapse. At the same time, the short half-life of nitric oxide means that such action will be restricted to a limited area, without the necessity for enzymatic breakdown or cellular reuptake.¹³

2. Increased levels of nitric oxide result in a decrease of conductivity in sensor nerves as a result of hyperpolarization of nerve endings and changes in potential of neuron membranes.¹⁴
3. There is an activation of metabolic processes in mitochondria nerve endings.¹⁵ This results in changes within the conduction of stimuli in cholinergic synapses.^{16,17}
4. A reflexory inhibition of ascending pain conduction tracts and activation of secretion of endorphins within the CNS by laser stimulation of acupuncture points.²⁶

Decrease in Bradykinin Levels:

Bradykinins, released from plasma protein at the site of injured tissue, elicit pain by stimulating nociceptive afferents in the skin and viscera. Mitigation of these elevated levels through therapeutic photobiomodulation will therefore result in a reduction of pain. The photobiomodulated induced decrease in plasma kallikrein, increase in kininase II and the increases in Nitric oxide are considered the contributors to the decrease in bradykinin levels.¹⁸

Blocked Depolarization of C Fiber Afferent Nerves:

Another extremely important analgesic event occurs when therapeutic photobiomodulation results in the blockage of the C fiber afferent nerves.²² These nonmyelinated fibers convey input signals from the periphery to the central nervous system and respond to various stimuli that can be thermal, mechanical, or chemical in nature.

Photoreceptors within the neuronal mitochondria absorb photonic energy which is then mediated and transduced into electrochemical changes.^{2,12} This results in a secondary cascade of intracellular events within the neuron that initiates a decrease in the following: mitochondrial membrane potential, available ATP required for nerve function and the maintenance of microtubules and molecular motors, dyneins and kinesins that are responsible for fast axonal flow.¹⁹ Therefore, it is a photonic induced neural blockade that slows the conduction velocity and reduces the amplitudes of the compound action potentials.²⁰ This photobiomodulatory reaction and consequential blockade is the mechanism that reduces nociceptive pain.²⁷

Increased Release of Acetylcholine:

There is an increase in the reaction time in the formation of acetylcholine following therapeutic photobiomodulation. The increased availability of this neuromodulator allows for a normalization of nerve signal transmissions within the peripheral and central nervous systems.²³

Axonal Sprouting and Nerve Cell Regeneration:

Several studies have documented the ability of laser therapy to induce axonal sprouting and some nerve regeneration in damaged nerve tissues. Where pain sensation is being magnified due to nerve structure damage, cell regeneration and sprouting assists in alleviating this maladaptive, neuropathic pain.^{24,25,28}

Therapeutic Dosage:

Therapeutic photobiomodulation is dependent upon the delivery of a therapeutic dosage of energy to the target nerve cells. Wavelength determines the depth of penetration and the power of the laser determines the delivery of the dosage. The current literature states that a physiological and biological response within the cells is achieved at a dosage of 2 to 12 Joules/cm².^{2, 27,28,29,30}

Incidental absorption of photons must be considered when trying to calculate the therapeutic dose. Body mass, color and thickness of the dermis and hair coat must be taken into consideration for successful, consistent results.

Prevention and treatment of superficial acute pain should be dosed at 2 to 6 Joules/cm².

A post-op incision site of 2 inches by 3 inches would require:

$$5.08 \text{ cm} \times 7.62 \text{ cm} = 38.7 \text{ cm}^2$$

$$38.7 \text{ cm}^2 \times 2 \text{ Joules/cm}^2 = 77.4 \text{ Joules/treatment}$$

Chronic pain that is deep within the tissues would require a dosage in the range of 7 – 12 Joules/cm²

Treatment of a 40 lb., dark skinned, long haired dog with chronic hip dysplasia would require:

$$8 \text{ cm} \times 8 \text{ cm} = 64 \text{ cm}^2$$

$$64 \text{ cm}^2 \times 8 \text{ Joules/cm}^2 = 512 \text{ Joules/treatment}$$

Frequency of Treatment:

Acute pain:

Aggressive phase: each day for 3 to 4 treatments

Transitional phase: (less frequent) every other day or twice per week until condition is resolved.

Chronic pain:

Aggressive phase: each day or every other day for 3 to 4 treatments.

Transitional phase: every other day or twice per week until therapeutic goal has been achieved.

Maintenance phase: as often as needed to control pain and maintain a satisfactory quality of life.

Therapeutic Photobiomodulation as an Integral Part of a Multimodal Approach to Pain Management:

These are generic case examples. Each patient is unique and pain management plans need to be tailored to correspond to the patient and the owner's individual situation. The pharmacological portions of the treatment plan below are merely an example. Each practitioner will have their own standard of pharmacological care.

Case Examples:

Acute Pain

Canine Ovariohysterectomy; hospitalized for 24 hours.

Preemptive analgesia:

Morphine: 0.5 – 1.0 mg/kg SQ 30 minutes before general anesthesia.

Acepromazine: .02 mg/kg SQ.

Atropine: .04mg/kg SQ.

Preemptive and postsurgical analgesia:

Administration of photobiomodulation utilizing a non-contact sterile technique:

Dosage: 2 Joules/cm²

1. Stretched associated ligaments and to any manipulated visceral structures.
2. Incision before closure of peritoneum
3. Incision upon closure of dermis.

Postoperative analgesia:

Good nursing care: Ice, lubricate eyes, soft recovery area and support during recovery

Morphine: .5 – 1.0 mg/kg at 3 to 4 hours post-op.

Analgesia for night:

Buprenorphine: 0.01 mg/kg SQ.

Twenty-four hour analgesia:

Administration of photobiostimulation in a non-contact technique over the incision site:

Dosage: 2 – 4 Joules/cm²

NSAID: carprofen or meloxicam

Discharge analgesia:

Carprofen 4 mg/kg PO or tramadol 2 – 3 mg/kg PO.

Chronic Pain

DX: Bilateral degenerative joint disease of the coxofemoral joints; eight years duration.

Initial pharmacological plan:

Amantadine: 2 – 5 mg/kg PO sid. Treatment for central neuronal hyperexcitability (windup).

Carprofen: 4 mg/kg PO sid. NSAID

Gabapentin: a form without xylitol. 5 – 10 mg/kg bid.

Adequan®: 2 mg/lb. twice weekly for four weeks.

Therapeutic photobiomodulation:

Aggressive phase: every other day; at least three treatments; dosage 8 to 10 Joules/cm². Include treatments of the lumbar spine and acupuncture points: GB 29 to 30, BL 40 – 54, GB 34 and BL 11.

Transitional phase: twice/week on both hips and lumbar spine with constant re-evaluation at each therapy session.

Maintenance phase: therapy as needed (one treatment every 3 – 5 weeks) to maintain comfort.

Nutrition and nutraceuticals:

Evaluate diet

Omega 3's

Chondroitin

Physical therapy

Stretching exercises

Rehabilitation exercises

Swimming

Modifications to environment

Ramps

Rugs on slippery floors

Limit access to stairs

Conclusions:

Therapeutic photobiomodulation is a scientifically proven modality that is an extremely effective tool for the management of pain.³¹ The number of applications of this modality in daily practice is expanding exponentially. It is one that is easily woven into pain management protocols that already exist in the practice. For many practices, it has become part of the standard of care, and not simply reserved for those cases that fail to respond to traditional methods.

References:

1. Jiang, N., Cooper, B.Y., Nemenov, M.I. Non-invasive diode laser activation of transient receptor potential proteins in nociceptors. *Proc. Of SPIE Vol. 6428, 64809, 2007.*
2. Chow R. Phototherapy and the peripheral nervous system. *Photomed Laser Surg.* 2011 Sep;29(9):591-2
3. Yan W, Chow R, Armati PJ. Inhibitory effects of visible 650-nm and infrared 808-nm laser irradiation on somatosensory and compound muscle action potentials in rat sciatic nerve: implications for laser-induced analgesia. *J Peripher Nerv Syst.* 2011 Jun;16(2):130-5.
4. Chow R, Armati P, Laakso EL, Bjordal JM, Baxter GD. Inhibitory effects of laser irradiation on peripheral mammalian nerves and relevance to analgesic effects: a systematic review. *Photomed Laser Surg.* 2011 Jun;29(6):365-81.

5. Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomized placebo or active-treatment controlled trials. *Lancet*. 2009 Dec 5; 374(9705):1897-908. Epub 2009 Nov 13. Review. Erratum in: *Lancet*. 2010 Mar 13;375(9718):894.
6. Eells, J. T. et al. *Proceedings National Academy of Science* 2003; 100:3439-3444
7. T.I. Karu. *Low power laser therapy*. In: Biomedical Photonics Handbook. Ch. 48, Editor-in-chief Tuan Vo-Dinh, Boca Raton: CRC Press. 2003.
8. Huang Y-Y, Chen A C-H, Carroll JD, Hamblin MR. Biphasic dose response in low-level light therapy. *Dose Response*, 2009, 7, 358-383.
9. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The Nuts and Bolts of Low-level Laser (Light) Therapy. *Ann Biomed Eng*. 2012 Feb;40 (2):516-33.
10. Montesinos M 1988, 'Experimental effects of Low Power Laser in Encephalon and Endorphin Synthesis LASESR', *Journ Eur Med Laser Ass.*, vol. 1, no. 3, pp. 2-7.
11. Oswald Steward: *Functional neuroscience* (2000), page 116
12. Hamblin, M. R., Demidova-Rice, T. N. Cellular Chromophores and Signaling in Low Level Light Therapy. Wellman Center for Photomedicine, Mass. General Hospital. Proc. of SPIE Vol. 642802, 2007
13. Huang Y-Y, Chen AC, Carroll JD, Hamblin MR. Biphasic Dose Response in Low Level Light Therapy, Sep 1; 7(4): 358-83.
14. Hopper RA, Garthwaite J. *J Neurosci*. 2006 Nov 8;26(45):11513-21
15. Rochkind S. and Ouaknine GE.(1992) "Review: new trend in neuroscience: low-power laser effect on peripheral and central nervous system (basic science, preclinical and clinical studies)". *Neurological Research* 14:2-11.
16. Rochkind S., Nissan M., Barr-Nea L., Razon N., Schwartz M., Bartal A . (1987) "Response of peripheral nerve to HeNe laser: experimental studies" *Lasers in Surgery and Medicine* 7:441-443.
17. Rochkind S. (1992) "Spinal cord and brain transplantation benefitted by low-power laser irradiation." *Lasers in Medical Science* 7:143-151.
18. Pomeranz, B. and Chiu, D. "Naloxone Blockade of Acupuncture Analgesia: Endorphin Implicated." *Life Sci* 1976 Dec. 1; 19(11) 1757-62.
19. Chow, R.T. and Barnsley, L, 2005. Systematic Review of the Literature of Low-Level Laser Therapy(LLLT) in the Management of Neck Pain. *Lasers Surg Med* 2005 Jul; 37(1): 46-52.
20. Huang Y-Y, Chen AC-H, Wu Q, Sharma SK, Hamblin MR. Comparison of cellular responses induced by low level light in different cell types. In: Hamblin MR, Anders JJ, Waynant RW, Editors. *Mechanisms for Low-Light Therapy V*, Bellingham, WA, The International Society for Optical Engineering,. Proc SPIE 2010, Vol. 7552: 75520A-1
21. Chow RT, David MA, Armati PJ. 830 nm laser irradiation induces varicosity formation, reduces mitochondrial membrane potential and blocks fast axonal flow in small and medium diameter rat dorsal root ganglion neurons: implications for the analgesic effects of 830 nm laser. *J Peripher Nerv Syst*. 2007 Mar;12(1):28-39.

22. OHNO-SHOSAKU, T., SAWADA, S. & YAMAMOTO, C. (1995). Presynaptic modulation of glutamatergic and GABAergic transmissions in rat cultured hippocampal neurons. 4th IBRO World Congress of Neuroscience, Kyoto, Japan, Abstract P176.
23. Nicolau, R.A., Martinez, M.S., Rigau, J. and Tomás, J. Neurotransmitter release changes induced by low power 830 nm diode laser irradiation on the neuromuscular junctions of the mouse. *Lasers Surg Med* 2004; 35(3): 236-41.
24. Xingjia, W.U., Alberico, S., Erbele, I., Moges, H., Pryor, B., Anders, J. *Differential Response of Neurons to Light Irradiation in an in vitro Diabetic Model*. Dept. of Anatomy, Physiology and Genetics, USUHS, Bethesda, MD. ASLMS proceedings 2010.
25. Huang YY, Tedford CE, McCarthy T, Hamblin MR. Low level laser therapy reduces oxidative stress in cortical neurons in vitro. In : Hamblin MR, Anders JJ, Waynant RW, Editors. Mechanisms for Low-Light Therapy VII, Bellingham, WA, The International Society for Optical Engineering, Proc SPIE 2012
26. Naeser, M. A., Neurological rehabilitation: acupuncture and laser acupuncture to treat paralysis in stroke, other paralytic conditions, and pain in carpal tunnel syndrome. *J Alt Compl Medicine*. 1997;3:425-428
27. Chow, R., Armati, P., Laakso, E-Liisa, Bjordal, J.M., Baxter, D.G. Inhibitory Effects of Laser Irradiation on Peripheral Mammalian Nerves and Relevance to Analgesic Effects: A Systematic Review. *Photomedicine and Laser Surgery*. Volume X, Number X, 2011. Pp. 1–17
28. Anders, J.J., Geuna, S., Rochkind, S. Phototherapy promotes regeneration and functional recovery of injured peripheral nerve. *Neurological Research*, 2004, Volume 26, March.
29. Bjordal J. M., Johnson M.I., Iversen V., Aimbire F., Lopes-Martins, R.A.B. *Photomedicine and Laser Surgery*. 2006, 24(2): 158-168. doi:10.1089/pho.2006.24.158.
30. Weersink, R., White, R., Lilge, L. Light dosimetry for Low Level Laser therapy: Accounting for difference in tissue and depth. *Proc. of SPIE Vol. 6428,642803*. 2007.
31. Chow, R.T., Johnson, M., Lopes-Martins, R., Bjordal, J.M.. Efficacy of low-level laser therapy in the management of neck pain: a systemic review and meta-analysis of randomized placebo or active-treatment controlled trials. *Lancet* 2009; 374: 1897-908.

